Background {#Sec1}
==========

Pulmonary pleomorphic carcinoma (PPC) is rare, with an incidence of 0.1--0.4 % of all non-small lung cancers (NSCLC) \[[@CR1]--[@CR5]\]. According to the World Health Organization classification report in 2004 \[[@CR4]\], pulmonary pleomorphic carcinoma is defined as poorly differentiated adenocarcinoma, squamous cell carcinoma or large cell carcinoma, containing a component of spindle or giant cells with a sarcomatoid tumor component of at least 10 % \[[@CR4]\]. Although clinical outcome is stage-dependent, it follows a more aggressive clinical course and has a worse prognosis than other histological types of NSCLC \[[@CR6]--[@CR10]\]. Furthermore, some recent reports have noted that PPC is often refractory to chemotherapy regimens which provide active treatment for NSCLC \[[@CR8]--[@CR12]\]. Due to its rarity, no optimal treatment for PPC has yet been established.

In NSCLC, the discovery that somatic alterations of driver gene, including *epidermal growth factor receptor* (*EGFR*) and *anaplastic large kinase* (*ALK*) gene, are found in a subset of lung adenocarcinomas and are associated with sensitivity to molecular target therapy has provided a rationale for the development of therapies in NSCLC \[[@CR13]--[@CR15]\]. Several reports noted that *EGFR* mutations were recognized in 15--20 % of patients with PPC but that the response to EGFR tyrosine kinase receptor inhibitor (TKI) was weak and transient as a consequence of tumor heterogeneity \[[@CR8], [@CR10], [@CR11], [@CR16]--[@CR18]\].

Here, we retrospectively analyzed the efficacy of chemotherapy and molecular targeted therapy in patients with advanced or metastatic PPC, and characterized their somatic alteration status, particularly for *EGFR* mutation, *K*-*ras* mutation, and ALK immunohistochemistry (IHC).

Patients and methods {#Sec2}
====================

Patient selection {#Sec3}
-----------------

PPC was diagnosed according to the 2004 World Health Organization classification \[[@CR4]\]. Diagnoses were based on light microscopy findings and confirmed by IHC examination. The histological diagnosis was reviewed by one of the authors (K.T.). From January 1998 to April 2010, 65 patients were histologically diagnosed with PPC by surgical resection, transbronchial lung biopsy, or computed tomography (CT) guided needle biopsy at our institution. Of these 65, 13 had received chemotherapy and 3 had received concurrent chemoradiotherapy, giving a total of 16 consecutive patients for final enrollment as subjects of this study. The protocol was approved by the institutional review board of National Cancer Centre Hospital and we reviewed the medical records of all of these patients.

EGFR mutation, KRAS mutation, and ALK-IHC analysis {#Sec4}
--------------------------------------------------

Activating EGFR mutations (i.e., exon 19 in-frame deletion and exon 21 L858 R missense mutations) and KRAS mutation in exon 2 (codon 12 and codon 13) were examined in paraffin-embedded tumor specimens by high-resolution melting assay using LCGreen (Idaho Technology) on a LightCycler (Roche Diagnostics), as previously described \[[@CR19]\]. These PCR products were denatured at 95 °C for 10 min and cooled to 40 °C to promote the formation of heteroduplexes. The LightCycler capillary was transferred to an HR-1 (Idaho Technology), an high-resolution melting assay instrument, and heated at a transition rate of 0.3 °C/s. Data were acquired and analyzed using the accompanying software (Idaho Technology). After normalization and temperature-adjustment steps, melting curve shapes from 78.5 to 85.5 °C were compared between the tumor samples and control samples. Human Genomic DNA (Roche Diagnostics) was used as the negative control sample with wild-type EGFR. Samples revealing skewed or left-shifted curves as compared with the control samples were judged to have mutations without positive controls.

*ALK* gene fusions were analyzed by immunohistochemistry. Four-micrometer-thick sections were deparaffinized. Heat-induced epitope retrieval was performed with targeted retrieval solution (pH 9) (Dako, Carpinteria, CA). The slides were then incubated with primary antibodies against ALK protein (1:40, 5A4; Abcam, Cambridge, UK) for 30 min at room temperature. Immunoreactions were detected using the EnVision-FLEX and LINKER (Dako). The reactions were visualized with 3,3′-diaminobenzidine, followed by counterstaining with hematoxylin.

To evaluate the genetic heterogeneity of PPC, we also investigated EGFR IHC in two different histological types. For immunohistochemical staining, formalin-fixed, paraffin-embedded tissues were cut into 4-μm-thick sections and deparaffinized, then subject to heat-induced epitope retrieval with Target Retrieval Solution (Dako, Carpinteria, CA, USA). The primary antibody used was a rabbit monoclonal antibody against human EGFR with the DEL (E746-A750del) mutation (1:100, clone 6B6, Cell Signaling Technology, Danvers, MA, USA) and a rabbit monoclonal antibody against human EGFR with the L858R mutation (1:200, clone 43B2, Cell Signaling Technology) \[[@CR20]\]. Antibodies were diluted in SignalStain (Cell Signaling Technology) and the slides were incubated with each primary antibody for 1 h at room temperature. Immunoreactions were detected using the EnVision Plus system (Dako) and 3, 3′-diaminobenzidine, followed by counterstaining with hematoxylin.

Assessment and analysis {#Sec5}
-----------------------

Clinical information was obtained from medical records. Clinical disease staging was reassessed according to the latest International Union Against Cancer staging criteria \[[@CR21]\]. Response to chemotherapy and survival were assessed retrospectively and classified according to the Response Evaluation Criteria for Solid Tumors, version 1.1 \[[@CR22]\]. Progression-free survival (PFS) was defined as the time from the first day of chemotherapy to detection of the earliest signs of disease progression or death from any cause. Overall survival (OS) was defined as the time from the first day of chemotherapy to the last day on which the patient was confirmed to be alive or dead from any cause. Survival was estimated using the Kaplan--Meier method. Fisher's exact and χ^2^ test was used to examine the association of two categorical variables. Differences with probability values of \<0.05 were considered statistically significant. STATA version 12 (StataCorp LP, College Station, TX, USA) was used for all analyses.

Results {#Sec6}
=======

Patient characteristics {#Sec7}
-----------------------

Clinical characteristics of the 16 patients who were finally enrolled are listed in Table [1](#Tab1){ref-type="table"}. Median age was 61 years (range 43--77 years). Ten patients (62.5 %) were male and six (37.5 %) were female. Twelve patients (75.0 %) were ex-smokers and their median pack-years was 45.5 (range 17--124). Ten patients (62.5 %) had relapsed after curative surgery, four (25.0 %) were initially diagnosed with advanced disease at stage IV, and two (12.5 %) were diagnosed with locally advanced disease at stage IIIA. Among the relapsed patients who had undergone curative surgery, none had received adjuvant chemotherapy. Two patients with stage IIIA disease and one who had relapse of mediastinal and supraclavicular lymph node metastases received concurrent chemoradiotherapy. Thirteen patients (81.3 %) received systemic chemotherapy, including cytotoxic agents or molecular targeted agents. Ten patients were diagnosed by the resected primary tumor; of the other six, three were diagnosed by CT guided needle biopsy and three by autopsy.Table 1Patient characteristicsCharacteristicNumber of patients (n = 16)Sex Male10 (62.5 %) Female6 (37.5 %)Age (years) Median (range)61 (43--77)ECOG-PS 03 (18.8 %) 110 (62.5 %) 23 (18.8 %)Smoking status Never smoker4 (25.0 %) Ex-smoker12 (75.0 %)Pack-years^a^ Median (range)45.5 (17--124)Clinical stage IIIA2 (12.5 %) IV4 (25.0 %) Recurrence10 (62.5 %)Diagnostic procedure Surgery10 (62.5 %) CT-NB3 (18.8 %) Autopsy3 (18.8 %)Pathological features Epithelial component  Adenocarcinoma7 (43.8 %)  Squamous cell carcinoma2 (12.5 %)  Adenosquamous carcinoma1 (6.3 %)  Large cell carcinoma4 (25.0 %)  NOS2 (12.5 %) Sarcomatoid component  Spindle cell0 (0.0 %)  Giant cell2 (12.5 %)  Spindle cell and giant cell14 (62.5 %)*CT-NB* CT-guided needle biopsy, *NOS* not otherwise specified^a^Ex-smoker (n = 12)

Pathological features {#Sec8}
---------------------

On histologic review of the malignant epithelial component, adenocarcinoma was identified in seven cases (43.8 %), large cell carcinoma in four (25.0 %), squamous cell carcinoma in two (12.5 %), NSCLC in two (12.5 %), and adenosquamous carcinoma in one (6.3 %). For the sarcomatoid component, two cases (12.5 %) had giant cell tumors. Of the 14 cases (87.5 %) who had both spindle cell tumors and giant cell tumors, the spindle cell tumor was dominant in nine (56.3 %) while the giant cell was dominant in five (31.3 %).

Molecular profile {#Sec9}
-----------------

*EGFR* mutation, *KRAS* mutation and ALK-IHC were investigated in the 14 patients whose tumor specimens were available (Table [2](#Tab2){ref-type="table"}). *EGFR* mutation was observed in 2 (14.3 %) of these 14 patients. The histological features of the patient harboring *EGFR* exon 19 deletion was adenosquamous carcinoma with spindle cell and giant cell tumor and that of the patient harboring *EGFR* L858R mutation in exon 21 was large cell carcinoma with spindle cell and giant cell tumor. *KRAS* mutation was observed in three patients (21.4 %). Two patients with *EGFR* mutation were never smoker, while all patients with *KRAS* mutation were ex-smokers. No patient was positive for ALK-IHC.Table 2Association between pathological findings and molecular profileNo.SexDiagnostic procedureSmoking indexEGFR mutationKRAS mutationALK IHCPathological featuresEpithelial componentSarcomatoid component1MSurgery2100WildMutatedNegativeAdenoGiant cell \> Spindle cell2FSurgery0Exon 19 delWildNegativeAdenosquamousSpindle cell \> Giant cell3MSurgery1200WildWildNegativeAdenoSpindle cell \> Giant cell4FSurgery0WildWildNegativeAdenoSpindle cell \> Giant cell5MSurgery400WildWildNegativeAdenoSpindle cell \> Giant cell6MSurgery1800WildWildNegativeSquamousSpindle cell \> Giant cell7FSurgery600WildWildNegativeAdenoSpindle cell \> Giant cell8FSurgery345WildMutatedNegativeLargeGiant cell \> Spindle cell9MAutopsy495NANANANOSGiant cell \> Spindle cell10MBiopsy2480WildWildNegativeNOSGiant cell11MAutopsy480WildWildNegativeAdenoGiant cell12MBiopsy1600WildMutatedNegativeSquamousSpindle cell \> Giant cell13MSurgery660WildWildNegativeLargeGiant cell \> Spindle cell14MAutopsy1160WildWildNegativeAdenoGiant cell \> Spindle cell15FSurgery0Exon 21 L858RWildNegativeLargeSpindle cell \> Giant cell16FBiopsy0NANANALargeSpindle cell \> Giant cell*IHC* immunohistochemistry, *NOS* not otherwise specified, *Adeno* adenocarcinoma, *Squamous* squamous cell carcinoma, *Large* large cell carcinoma, *Adenosquamous* adenosquamous carcinoma

Next, regarding the two cases harboring *EGFR* mutation, we evaluated the mutated EGFR protein expression using a mutation-specific antibody against *EGFR* mutations in both the epithelial and sarcomatoid components. In patient No. 2, we found that IHCs by mutation-specific antibody were positive in adenocarcinoma (Fig. [1](#Fig1){ref-type="fig"}a), squamous cell carcinoma (Fig. [1](#Fig1){ref-type="fig"}b), and sarcomatoid components (Fig. [1](#Fig1){ref-type="fig"}c). And patient No. 15 progressed after concurrent chemoradiotherapy and so we could not check the mutated EGFR protein expression in both the epithelial and sarcomatoid components.Fig. 1Two representative cases harboring *EGFR* mutation by mutation-specific antibody against *EGFR* mutations in both epithelial and sarcomatoid components. **a** adenocarcinoma component in patient No. 2, ×20; **b** squamous cell carcinoma component in patient No. 2, ×20; **c** sarcomatoid component in patient No. 2, ×20; **d** sarcomatoid component in patient No. 15, ×20

Treatment and efficacy {#Sec10}
----------------------

Of the 13 patients with advanced stage disease, 11 patients received cytotoxic chemotherapy as first-line chemotherapy. Among them, however, no patient achieved an objective response, except one patient (No. 6) who received docetaxel as second-line chemotherapy and achieved a partial response. In all patients, median PFS for first-line chemotherapy was 1.5 (95 % CI 0.6--2.5) months and OS was 7.2 (95 % CI 1.4--10.3) months (Table [3](#Tab3){ref-type="table"}). We also identified one patient (No. 13) who achieved stable disease of about 9 years' duration without progression after undergoing small intestinal resection for ileus due to a postoperative recurrence lesion in the small intestine and then receiving four cycles of cisplatin and gemcitabine treatment for hilar lymph node and bone metastases. One patient (No. 2) harboring *EGFR* exon 19 deletion was treated with gefitinib after postoperative recurrence of mediastinal lymph node and achieved a complete response of about 35 months (Fig. [2](#Fig2){ref-type="fig"}). Two months after she declined further treatment with gefitinib because of hemoptysis, she developed progressive disease in a mediastinal lymph node and thoracic spine metastases. All three patients who received concurrent chemoradiotherapy with cisplatin plus vinorelbine achieved a partial response (Table [3](#Tab3){ref-type="table"}). Although two patients had early recurrence, the third is alive without progression more than 5 years after completing chemoradiotherapy. One patient (No. 15) harboring *EGFR* exon 21 point mutation developed multiple brain metastases and carcinomatous meningitis immediately after chemoradiotherapy and was then treated with best supportive care without EGFR-TKI because of poor general condition.Table 3Treatment results by systemic chemotherapy and chemoradiotherapyNo.SexAgeStagePSEGFR mutation statusInitial treatmentORPFS (mos)OS (mos)Outcome1M55Relapsed1WildDTXPD0.77.3Died2F69Relapsed1Exon 19 delGefitinibCR35.153.9Died3M60Relapsed1WildCBDCA + PTXPD0.93.7Died4F45Relapsed0WildGefitinibPD1.710.7Died5M63Relapsed1WildCBDCA + PTXPD0.612.7Died6M62Relapsed1WildCDDP + GEMPD2.518.7Died7F53Relapsed2WildCBDCA + PTXPD0.41Died8F55Relapsed1WildDTXPD0.71.4Died9M56Advanced1NACBDCA + PTXPD0.61.0Died10M77Advanced2WildCBDCA + ETPPD1.57.2Died11M43Advanced1WildCBDCA + PTXSD4.510.3Died12M62Advanced2WildCBDCA + PTXNE0.40.4Died13M56Relapsed0WildCDDP + GEMNE109.2109.2Alive14M65Stage IIIA1WildCDDP + VNR + TRTPR5.06.6Died15F66Relapsed1Exon 21 L858RCDDP + VNR + TRTPR3.96.9Died16F66Stage IIIA0NACDDP + VNR + TRTPR65.465.4Alive*PS* performance status, *OR* overall response, *PFS* progression-free survival, *OS* overall survival, *DTX* docetaxel, *CBDCA* carboplatin, *PTX* paclitaxel, *CDDP* cisplatin, *GEM* gemcitabine, *ETP* etoposide, *VNR* vinorelbine, *TRT* thoracic radiotherapy, *SD* stable disease, *CR* complete response, *PD* progressive disease, *NE* not evaluable, *PR* partial responseFig. 2Chest computed tomography images of mediastinal lymph nodes (\#4R) before (**a**) and 6 months after gefitinib treatment (**b**)

Discussion {#Sec11}
==========

Previous retrospective studies and case reports suggested that PPC is often refractory to the chemotherapy regimens used in active treatment for NSCLC \[[@CR8]--[@CR11]\]. This retrospective study also found that PPC is an aggressive tumor associated with high cell proliferation and that palliative chemotherapy is associated with a poor response in advanced PPC, with a few notable exceptions.

With regard to chemoradiotherapy for locally advanced PPC, all three patients achieved a partial response in our study. Although two patients had early recurrence, the third is alive without progression more than 5 years after completing chemoradiotherapy. Some reports revealed that PPC treated with chemoradiotherapy achieved an objective response without recurrence \[[@CR10], [@CR11]\]. These results if confirmed suggest that chemoradiotherapy commonly used for NSCLC should be administered in unresectable stage III disease with pleomorphic carcinoma.

Several recent reports have described cases of PPC that responded to cytotoxic chemotherapy containing platinum and gemcitabine \[[@CR8]--[@CR12], [@CR23]\]. Tamiya et al. mentioned that high expression of human equilibrative nucleoside transporter 1 (hENT1), the major transporter of gemcitabine, might be associated with high sensitivity to gemcitabine in PPC \[[@CR12]\]. We also experienced one patient who achieved long-term stable disease without progression after receiving cisplatin and gemcitabine treatment. We propose that cisplatin and gemcitabine treatment may be an active chemotherapy for PPC.

In this study, we also investigated *EGFR* mutation, *KRAS* mutation and ALK-IHC in the 14 patients with PPC whose tumor specimens were available. We found that two (14.3 %) of these patients harbored *EGFR* mutation. One patient treated with gefitinib achieved a complete response, which was moreover sustained for about 35 months. Previous reports suggested that the incidence of *EGFR* mutation was about 15--20 % and that the response to gefitinib was weak and transient \[[@CR8], [@CR10], [@CR11], [@CR16]--[@CR18]\]. Kaira et al. independently investigated *EGFR* mutations in both the adenocarcinomatous and sarcomatoid components of three patients with *EGFR* mutation and detected *EGFR* mutations in the adenocarcinomatous component but not in the sarcomatoid component in all cases. Ushiki et al. revealed a case of PPC whose adenocarcinoma cells had an exon 19 deletion and whose sarcomatous cells had both the deletion 19 and 20 T790 M *EGFR* mutations \[[@CR16]\]. In our present study, we could not clearly separate epithelial tumor cells from sarcomatoid tumor cells because tumor tissue consisted of a mixture of both components. We then investigated IHC by mutated EGFR-specific antibody in the two different histological types to evaluate the genetic heterogeneity of PPC. We found that mutated EGFR protein expression was positive in both components. We consider that our results are unlikely to be false positives, because mutation-specific antibodies against EGFR mutation have high specificity in spite of low sensitivity \[[@CR20]\]. Tumorigenesis in lung cancer is known to be a multistage process by which monoclonal cancer cells gradually become heterogeneous owing to clonal evolution and genetic/epigenetic instability \[[@CR24]--[@CR27]\]. Applying computational analysis to the deep sequencing data of NSCLC samples, Govindan et al. suggested that EGFR mutation might be acquired at the very initial phase of tumorigenesis \[[@CR28]\]. We consider that the difference in the *EGFR* mutational heterogeneity of PPC between the epithelial and sarcomatoid components represents the point at which clonal evolution occurred. Additionally, our results also suggest that driver gene alteration such as *EGFR* should be investigated in the treatment of advanced PPC.

One limitation of our study is that the sample size was small, due to the rarity of this condition. Additionally, 10 of 16 patients diagnosed from the resected primary tumor did not undergone rebiopsy at the start of chemotherapy. For this reason, we did not attempt to identify which component of PPC relapsed.

Conclusions {#Sec12}
===========

All the patients who received concurrent chemoradiotherapy achieved at least a partial response and if confirmed, chemoradiotherapy should be considered an effective modality in locally advanced disease. Although this study demonstrated that advanced PPC responds poorly to chemotherapy, further clinical trials are needed to investigate the role of palliative chemotherapy for PPC, including platinum and gemcitabine treatment. Additionally, one patient with *EGFR* mutation achieved a long-term complete response. We therefore recommend evaluating driver gene alteration, such as *EGFR,* in the treatment of advanced PPC.
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